Poster Presentation Lancefield International Symposium for Streptococci and Streptococcal Diseases 2025

Group A Streptococcus-derived vesicles as an antigen presenting platform for vaccine development (#304)

Meztlli Gaytan 1 , Rebecca Dookie 1 , Staffan Normark 1 , Birgitta Henriques-Normark 1
  1. Karolinska Institutet, Solna, STOCKHOLM, Sweden

An effective vaccine against Streptococcus pyogenes (Group A streptococcus, GAS) is urgently needed. Bacterial membrane vesicles (MVs) had been successfully used in vaccine formulations against Neisseria meningitidis1 and Streptococcus pneumoniae2. MVs have a great potential as a novel vaccine platform as they can activate the immune system, work as adjuvant and deliver antigens in their native conformation. In this study, we demonstrate that intranasal immunization with GAS-derived vesicles (GAS-MVs) elicits a strong humoral and cellular response in mice. Our results highlight the potential of GAS-derived vesicles as a novel antigen presenting platform that can aid in the development of a vaccine vs S. pyogenes.